REG - Futura Medical PLC - Futura Medical AGM Results

Futura MedicalAnnouncement

28/06/2022 16:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220628:nRSb5207Qa&default-theme=true

RNS Number : 5207Q  Futura Medical PLC  28 June 2022

 

28 June 2022

 Futura Medical plc

("Futura" or the "Company")

Futura Medical Announces Annual General Meeting Results

 

 

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio
of innovative products based on its proprietary, transdermal DermaSys® drug
delivery technology and currently focused on sexual health and pain, today
announces that at its Annual General Meeting, held today at 10:00am BST, the
shareholders duly passed all resolutions.

 

The total number of votes received on each resolution were as follows:

 

 

                                                                                                   Voting For                                                    Voting Against
                    Number of votes(i)                                                             %                              Number of votes                %                                Total Votes                      % ISC        Votes withheld(ii)
 Resolution 1       To accept the Annual Report and accounts                                       132,535,568                    95.80%                         5,769,918                        4.20%                            138,305,486  48.14%              70,831
 Resolution 2       To appoint Jeff Needham as a Director                                          138,246,246                    99.98%                         27,676                           0.02%                            138,273,922  48.13%              102,395
 Resolution 3       To appoint Andrew Unitt as a Director                                          138,250,441                    99.98%                         23,481                           0.02%                            138,273,922  48.13%              102,395
 Resolution 4       To re-elect Ken James as a Director                                            138,243,746                    99.98%                         30,676                           0.02%                            138,274,422  48.13%              101,895
 Resolution 5       To re-appoint Grant Thornton UK LLP as Auditor                                 138,244,578                    99.96%                         49,908                           0.04%                            138,294,486  48.14%              81,831
 Resolution 6       To authorise the Directors to determine the remuneration of Grant Thornton UK  138,276,015                    99.97%                         40,471                           0.03%                            138,316,486  48.14%              59,831
                    LLP
 Resolution 7       To authorise the directors of the Company to issue and allot relevant          138,239,449                    99.95%                         65,970                           0.05%                            138,305,419  48.14%              70,898
                    securities (up to 1/3 of the existing issued share capital) pursuant to
                    section 551 of the Companies Act 2006
 Resolution 8(iii)  A Special Resolution empowering the Directors to disapply the pre-emption      138,150,793                    99.90%                         135,129                          0.10%                            138,285,922  48.13%              90,395
                    provision of section 561 of the Act in connection with an offer of equity
                    securities by way of a Rights Issue or up to an aggregate nominal value of
                    £28,729.00
 Resolution 9       A Special Resolution empowering the Directors to disapply the pre-emption      138,170,921                    99.92%                         111,934                          0.08%                            138,282,855  48.13%              93,462
                    provision of section 561 of the Act in connection with an offer of equity

                    securities to fund an acquisition or a capital transaction

 

ⁱ Where shareholders appointed the Chairman as their proxy with discretion
as to voting, their votes were cast in favour of the resolution

ⁱⁱ A vote withheld is not a vote in law and is not counted towards the
votes cast "For" or "Against" a resolution

ⁱⁱⁱ Special Resolution (75% majority required)

The total voting rights of the Company as at 10:00 am on 24 June 2022 (the
time by which shareholders wanting to vote at the AGM were required to be
entered on the register) was 287,296,527 ordinary shares of 0.2p each. The
Company does not hold any shares in treasury

 

-ENDS-

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: investor.relations@futuramedical.com
(mailto:Investor.relations@futuramedical.com)

Tel: +44 (0) 1483 685 670

www.futuramedical.com (http://www.futuramedical.com/)

Nominated Adviser and Sole Broker:

Liberum

Phil Walker/ Richard Lindley/ Ben Cryer/ Kane Collings

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

 

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile/ Zoe Bolt

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 882 9621

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative products based on its proprietary, transdermal
DermaSys® technology. Each DermaSys® formulation is separately patented and
specifically tailored for the selected indication and application, as well as
being optimised for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and consumer
healthcare markets as appropriate. Current therapeutic areas are sexual
health, including erectile dysfunction, and pain relief. Development and
commercialisation strategies are designed to maximise product differentiation
and value creation whilst minimising risk.

MED3000 is Futura's topical gel formulation that is a breakthrough treatment
for erectile dysfunction ("ED") through a unique evaporative mode of action.
Futura has conducted a Phase 3 study using MED3000 in ED, referred to as
"FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised,
double blind, placebo-controlled, home use, parallel group study delivering
highly statistically significant results compared to pre-treatment baseline,
consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3
(internationally accepted clinical trial endpoints in ED) with over 60% of
patients experiencing a clinically meaningful improvement in their ED.
MED3000 also begins to work immediately in some patients, with 60% of patients
seeing onset of their erection within 10 minutes of application. MED3000 is CE
marked in Europe and the UK as a clinically proven topical treatment
for adult men with erectile dysfunction.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(https://www.futuramedical.com/)

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGFLFESRFITFIF